ALIGOS THERAPEUTICS INC's ticker is ALGS and the CUSIP is 01626L105. A total of 78 filers reported holding ALIGOS THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,494 | -48.7% | 2,000 | -33.3% | 0.00% | – |
| Q2 2023 | $2,913 | -97.5% | 3,000 | -97.7% | 0.00% | – |
| Q1 2023 | $116,001 | +5071.7% | 132,724 | +5540.6% | 0.00% | – |
| Q4 2022 | $2,243 | -79.6% | 2,353 | -77.1% | 0.00% | – |
| Q3 2022 | $11,000 | -82.8% | 10,282 | -80.5% | 0.00% | – |
| Q2 2022 | $64,000 | -62.6% | 52,613 | -34.3% | 0.00% | – |
| Q1 2022 | $171,000 | -72.1% | 80,110 | +55.0% | 0.00% | – |
| Q4 2021 | $613,000 | -91.6% | 51,670 | -89.0% | 0.00% | -100.0% |
| Q3 2021 | $7,280,000 | +2146.9% | 469,404 | +2859.9% | 0.00% | – |
| Q2 2021 | $324,000 | -58.5% | 15,859 | -53.8% | 0.00% | – |
| Q1 2021 | $780,000 | +36.8% | 34,315 | +66.6% | 0.00% | – |
| Q4 2020 | $570,000 | – | 20,593 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 2,320,381 | $1,733,325 | 0.92% |
| TANG CAPITAL MANAGEMENT LLC | 3,329,048 | $2,486,799 | 0.35% |
| Vivo Capital, LLC | 3,547,030 | $2,649,631 | 0.29% |
| Pivotal bioVenture Partners Investment Advisor LLC | 743,215 | $555,182 | 0.22% |
| Newtyn Management, LLC | 920,000 | $687,240 | 0.17% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 631,887 | $472,020 | 0.14% |
| EcoR1 Capital, LLC | 3,948,360 | $2,949,425 | 0.10% |
| HHLR ADVISORS, LTD. | 2,309,764 | $1,725,394 | 0.04% |
| Baker Brothers Advisors | 2,076,400 | $1,551,071 | 0.01% |
| HARBOURVEST PARTNERS LLC | 18,783 | $14,031 | 0.01% |